Belated Good News: Merck Wins Accelerated Approval In Certain Triple Negative Breast Cancers

The Keytruda^® juggernaut marches onward, allowing Merck a consistent, exceedingly high revenue franchise, from which to fund partnerships in other worthwhile, high burden arenas, like HIV and COVID-19.

In truth, this news came out earlier this week, but there were sweet surprises last evening, so I'm just getting to it over coffee this morning. Here's the bit:

. . .The FDA granted accelerated approval to pembrolizumab combined with chemotherapy for treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1. . . .

As ever, Merck is very well positioned -- to once again be the world's most admired company, as the third decade of the 21^st Century opens in a few weeks (as it was, in the middle to late decades of the last century).

We remain hopeful, open and smiling here -- for a rekindling of that auspicious stature, in relation to the world at large, and specific portions of her precious human cargo. So, onward!

नमस्ते